Subcutaneous Injection Site Rotation: Preventing Lipohypertrophy and Bruising

If you're injecting subcutaneously more than twice a week, you'll eventually develop site-related issues. Lipohypertrophy (fatty thickening), persistent bruising, sub-q nodules, and scarring are all common. They're also mostly preventable with rotation discipline and minor technique fixes.

What lipohypertrophy actually is

Lipohypertrophy is fatty thickening of subcutaneous tissue caused by the local growth-promoting effects of repeated injection, particularly with insulin or insulin-like signaling peptides. It presents as soft, rubbery, painless lumps under the skin at injection sites.

Once formed, lipohypertrophy areas:

• Absorb peptide unpredictably — sometimes faster, sometimes slower, often less reliably
• Are less painful to inject into (less innervation in the thickened tissue), which paradoxically makes users prefer them — which makes the problem worse
• Take 6–12+ months to resolve once you stop injecting into them, sometimes longer

For GLP-1 users, injecting into lipohypertrophy areas is one of the under-appreciated reasons for inconsistent appetite suppression and weight-loss plateaus. The peptide isn't absorbing the way it did when sites were fresh.

The rotation pattern that actually works

The standard advice — "rotate sites" — is too vague to prevent the problem. A workable rotation system has three layers.

Layer 1: Major regions. The main subcutaneous injection regions are abdomen (avoiding 2-inch radius from navel), upper outer thighs, upper outer arms, and outer-upper buttocks (less common for self-injection). For most peptide users, abdomen and thighs are the primary regions.

Layer 2: Quadrants within regions. Divide each region into four quadrants. For abdomen: upper-left, upper-right, lower-left, lower-right (excluding navel area). Inject into a different quadrant each time.

Layer 3: Spacing within quadrants. Within a quadrant, space each injection at least 1 inch (2.5 cm) from your last injection in that quadrant. Within a quadrant, you have ~12–20 distinct injection sites.

Practical rotation calendar for daily injection (e.g., BPC-157 daily):

• Monday: upper-right abdomen
• Tuesday: upper-left abdomen
• Wednesday: lower-right abdomen
• Thursday: lower-left abdomen
• Friday: right thigh outer-upper
• Saturday: left thigh outer-upper
• Sunday: rest day or right arm outer-upper

This gives each region ~4-6 days between hits, which is enough recovery for most users.

For weekly injection (e.g., semaglutide, tirzepatide):

• Week 1: upper-right abdomen, point A
• Week 2: upper-left abdomen, point A
• Week 3: lower-right abdomen, point A
• Week 4: lower-left abdomen, point A
• Week 5: upper-right abdomen, point B (1+ inch from week 1's spot)
• Continue cycling

This pattern prevents weekly users from accumulating injections in the same exact spots.

Technique fixes that reduce site issues

Beyond rotation, technique affects bruising and tissue damage independent of where you inject.

1. Pinch and angle.

• Pinch a fold of subcutaneous tissue between thumb and forefinger
• Insert needle at 90° if you have adequate fat, 45° if you're lean
• Goal is to deposit in subcutaneous fat, not muscle

2. Slow injection.

• Push the plunger over 5–10 seconds, not 1–2
• Fast injection causes more local tissue trauma and bruising
• Hold for 5 seconds after fully depressed before withdrawing

3. Needle gauge and length.

• Most subcutaneous peptides do well with 30–31 gauge, 5/16 inch (8 mm) insulin syringes
• Smaller gauge (higher number) = thinner needle = less bruising, less local trauma
• Longer needles risk intramuscular injection in lean users

4. Avoid blood vessels visible at the surface.

• Bruising = needle hit a small vessel
• If you see a visible vein, move 1+ inch
• For visible bruise sites, give that area 4–6 weeks before reinjecting

5. Cold injection causes more pain.

• Take refrigerated peptide out 5 minutes before injecting (room-temperature fluid is less stinging)
• Don't warm via heat (microwave, hot water) — temperature spikes degrade peptide

6. Alcohol swab and dry.

• Swab the site, let it dry before injecting
• Wet alcohol stings during injection
• Dry alcohol just disinfects without the burn

Recognizing early lipohypertrophy

Early lipohypertrophy is reversible. Late lipohypertrophy is persistent.

Early signs:

• Slight rubbery firmness in an area you've injected several times
• Reduced pain on injection in that area (this is the warning sign — pain reduction means tissue is changing)
• Slightly faster absorption initially, slower later

Late signs:

• Visible or palpable lumps under skin
• Asymmetric appearance compared to non-injected mirror site
• Persistent inconsistency in peptide effect from that site

The intervention: stop using affected sites entirely. Rotate to fresh sites. Existing lipohypertrophy slowly resolves over months once injections stop.

Persistent sub-q nodules and what they mean

Some users develop firm nodules that don't resolve like classic lipohypertrophy. These can be:

• Sterile abscesses — local inflammatory reaction, usually painful or tender
• Granulomas — chronic inflammatory response, often related to excipients
• Lipohypertrophy — soft, painless, slow-resolving
• Infection — red, warm, painful, sometimes fluctuant; requires medical evaluation

If a nodule is painful, warm, growing, or accompanied by fever, get medical evaluation. If it's painless and stable, it's most likely a benign reaction that will resolve over months.

Site selection for specific peptides

GLP-1s (semaglutide, tirzepatide): abdomen is FDA-recommended primary site. Thighs work but with slightly different absorption kinetics. Rotate aggressively because of weekly chronic use.

GH-axis peptides (Sermorelin, CJC-1295/Ipamorelin): any subcutaneous site. Pre-bed protocols often default to abdomen out of convenience.

BPC-157: literature-recommended approach is subcutaneous near the injury site for tendon/ligament work. This conflicts with rotation discipline for chronic injury — adjust based on whether you're doing acute (4-6 weeks of focused near-site dosing) vs chronic protocols.

TB-500: any subcutaneous site; the systemic mechanism doesn't require local proximity to target tissue.

Bottom line

Site rotation isn't optional for chronic peptide users. Lipohypertrophy is preventable with a real rotation pattern, three or four small technique improvements eliminate most bruising, and the warning signs of early site issues are subtle but recognizable. Setting up a rotation system on day one of a new protocol is the easiest version of this problem to solve.